331 related articles for article (PubMed ID: 32393312)
1. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
2. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
Zhao MN; Su L; Song F; Wei ZF; Qin TX; Zhang YW; Li W; Gao SJ
Acta Haematol; 2024; 147(3):310-324. PubMed ID: 37926079
[TBL] [Abstract][Full Text] [Related]
3. Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.
Ma H; Cui J; Liu Z; Fang W; Lu S; Cao S; Zhang Y; Chen JA; Lu L; Xie Q; Wang Y; Huang Y; Li K; Tong H; Huang J; Lu W
Oncogene; 2023 Nov; 42(45):3331-3343. PubMed ID: 37752234
[TBL] [Abstract][Full Text] [Related]
4. A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.
Long J; Chen X; Shen Y; Lei Y; Mu L; Wang Z; Xiang R; Gao W; Wang L; Wang L; Jiang J; Zhang W; Lu H; Dong Y; Ding Y; Zhu H; Hong D; Sun YE; Hu J; Liang A
Cell Rep Med; 2023 Nov; 4(11):101286. PubMed ID: 37951217
[TBL] [Abstract][Full Text] [Related]
5. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
6. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
[TBL] [Abstract][Full Text] [Related]
7. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
[TBL] [Abstract][Full Text] [Related]
8. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
[TBL] [Abstract][Full Text] [Related]
9. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract][Full Text] [Related]
10. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
Jebanesan DZP; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Das S; Bijukumar NK; Balakrishnan B; Mathews V; Velayudhan SR; Balasubramanian P
Ann Hematol; 2024 Jun; 103(6):1919-1929. PubMed ID: 38630133
[TBL] [Abstract][Full Text] [Related]
12. Glutaminolysis is a metabolic dependency in FLT3
Gallipoli P; Giotopoulos G; Tzelepis K; Costa ASH; Vohra S; Medina-Perez P; Basheer F; Marando L; Di Lisio L; Dias JML; Yun H; Sasca D; Horton SJ; Vassiliou G; Frezza C; Huntly BJP
Blood; 2018 Apr; 131(15):1639-1653. PubMed ID: 29463564
[TBL] [Abstract][Full Text] [Related]
13. Characterization of FLT3-ITD
Travaglini S; Angelini DF; Alfonso V; Guerrera G; Lavorgna S; Divona M; Nardozza AM; Consalvo MI; Fabiani E; De Bardi M; Neri B; Forghieri F; Marchesi F; Paterno G; Cerretti R; Barragan E; Fiori V; Dominici S; Del Principe MI; Venditti A; Battistini L; Arcese W; Lo-Coco F; Voso MT; Ottone T
Blood Cancer J; 2020 Aug; 10(8):85. PubMed ID: 32843624
[TBL] [Abstract][Full Text] [Related]
14. FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia.
Tan Y; Xin L; Wang Q; Xu R; Tong X; Chen G; Ma L; Yang F; Jiang H; Zhang N; Wu J; Li X; Guo X; Wang C; Zhou H; Zhou F
Cancer Lett; 2024 Jun; 592():216933. PubMed ID: 38705564
[TBL] [Abstract][Full Text] [Related]
15. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Sung PJ; Selvam M; Riedel SS; Xie HM; Bryant K; Manning B; Wertheim GB; Kulej K; Pham L; Bowman RL; Peresie J; Nemeth MJ; Levine RL; Garcia BA; Meyer SE; Sidoli S; Bernt KM; Carroll M
Leukemia; 2024 Feb; 38(2):291-301. PubMed ID: 38182819
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.
Yashar WM; Curtiss BM; Coleman DJ; VanCampen J; Kong G; Macaraeg J; Estabrook J; Demir E; Long N; Bottomly D; McWeeney SK; Tyner JW; Druker BJ; Maxson JE; Braun TP
Mol Cancer Res; 2023 Jul; 21(7):631-647. PubMed ID: 36976323
[TBL] [Abstract][Full Text] [Related]
17. Targeting FLT3 mutations in AML: review of current knowledge and evidence.
Daver N; Schlenk RF; Russell NH; Levis MJ
Leukemia; 2019 Feb; 33(2):299-312. PubMed ID: 30651634
[TBL] [Abstract][Full Text] [Related]
18. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
[TBL] [Abstract][Full Text] [Related]
19. Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V.
Rai S; Tanaka H; Suzuki M; Espinoza JL; Kumode T; Tanimura A; Yokota T; Oritani K; Watanabe T; Kanakura Y; Matsumura I
Nat Commun; 2020 Aug; 11(1):4147. PubMed ID: 32811837
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways.
Li G; Yao J; Lu Z; Yu L; Chen Q; Ding L; Fang Z; Li Y; Xu B
Drugs R D; 2023 Dec; 23(4):439-451. PubMed ID: 37847357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]